X4 Pharmaceuticals, Inc.
$4.19
▼
-2.53%
2026-04-21 10:21:01
www.x4pharma.com
NCM: XFOR
Explore X4 Pharmaceuticals, Inc. stock price, valuation, financial statements, dividend history, analyst estimates, and long-term business fundamentals on StockSifting.
Market Cap
$372.04 M
Current Price
$4.19
52W High / Low
$6.63 / $1.35
Stock P/E
—
Book Value
$2.05
Dividend Yield
—
ROCE
-32.82%
ROE
-75.99%
Face Value
—
EPS
$-1.87
Exp Qtr EPS
—
Sector
Healthcare
Industry
Biotechnology
Employees
45
Beta
0.33
Debt / Equity
41.49
Current Ratio
10.16
Quick Ratio
9.98
Forward P/E
-4.25
Price / Sales
10.62
Enterprise Value
$197.06 M
EV / EBITDA
-2.51
EV / Revenue
5.61
Rating
None
Target Price
$11.67
EPS Forecast (FY)
—
Pros
- Balance sheet leverage appears manageable.
- Short-term liquidity looks comfortable.
- Valuation is not stretched on P/E basis.
Cons
- Return on equity is on the weaker side.
- Capital efficiency is modest.
- Operating margin is thin.
- Net margin is relatively low.
Sift Stocks
| S.No. | Name | Price | P.E. | Market Cap | Div Yld % | ROCE | ROE | 52Week High/ Low | Book Value |
|---|---|---|---|---|---|---|---|---|---|
| 1. | MiNK Therapeutics, Inc. | $12.82 | — | $63.66 M | — | 859.68% | 57.3% | $76 / $6.34 | $-3.02 |
| 2. | Design Therapeutics, Inc. | $13.16 | — | $809.14 M | — | -37.28% | -30.7% | $13.5 / $3.1 | $3.52 |
| 3. | Theravance Biopharma, Inc. | $16.72 | 8.29 | $877.44 M | — | -0.81% | 44.84% | $21.03 / $8.33 | $5.81 |
| 4. | MediWound Ltd. | $17.35 | — | $226.34 M | — | -41.75% | -63.86% | $22.5 / $14.9 | $3.4 |
| 5. | Evogene Ltd. | $0.8 | — | $7.92 M | — | -84.53% | -1.01% | $2.42 / $0.72 | $-0.01 |
| 6. | Seer, Inc. | $1.99 | — | $112.84 M | — | -27.82% | -25.08% | $2.41 / $1.65 | $4.61 |
| 7. | Foghorn Therapeutics Inc. | $5.51 | — | $310.52 M | — | -59.34% | 96.45% | $6.95 / $3.27 | $-1.92 |
Quarterly Results
Figures shown in M / B
| Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | |
|---|---|---|---|---|---|---|
| Sales | 2.57 M | 1.76 M | 1.97 M | 28.81 M | 1.43 M | — |
| Operating Profit | -23.7 M | -27.51 M | -26.23 M | -9.44 M | -35.72 M | — |
| Net Profit | -23.93 M | -29.82 M | -25.74 M | 0.28 M | -39.82 M | — |
| EPS in Rs | -0.26 | -0.33 | -0.28 | 0 | -0.44 | -5.48 |
Profit & Loss
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Sales | 35.11 M | 2.56 M | 0 M | 0 M |
| Operating Profit | -86.88 M | -141.4 M | -107.52 M | -88.08 M |
| Net Profit | -79.2 M | -37.45 M | -101.17 M | -93.87 M |
| EPS in Rs | -0.87 | -0.41 | -1.11 | -1.03 |
Balance Sheet
Figures shown in M / B
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Total Assets | 290.46 M | 146.45 M | 147.26 M | 155.59 M |
| Total Liabilities | 104.17 M | 124.3 M | 96.16 M | 81.53 M |
| Equity | 186.29 M | 22.15 M | 51.1 M | 74.05 M |
| Current Assets | 261.58 M | 112.17 M | 122.08 M | 128.68 M |
| Current Liabilities | 25.76 M | 32.88 M | 22.86 M | 22.32 M |
Cash Flow
Last available yearly cash flow history
| 2025 | 2024 | 2023 | 2022 | |
|---|---|---|---|---|
| Operating CF | -85.62 M | -130.9 M | -96.51 M | -77.1 M |
| Investing CF | 8.15 M | 66.99 M | -14.88 M | -0.1 M |
| Financing CF | 238.63 M | 20.29 M | 88.52 M | 117.23 M |
| Free CF | -88.62 M | -138.23 M | -96.57 M | -77.2 M |
| Capex | -3 M | -7.33 M | -0.06 M | -0.1 M |
5Y Margin & Growth History
Last 5 year derived history from yfinance annual statements
| 2024 | 2023 | 2022 | 2021 | |
|---|---|---|---|---|
| Revenue Growth % | — | — | — | — |
| Earnings Growth % | 62.98% | -7.78% | — | — |
| Profit Margin % | -1464.61% | — | — | — |
| Operating Margin % | -5529.96% | — | — | — |
| Gross Margin % | 68.83% | — | — | — |
| EBITDA Margin % | -1078.45% | — | — | — |
Dividend & Split History
Latest dividend and stock split events stored from yfinance
Dividend History
No dividend history available.
Stock Splits
| Date | Split |
|---|---|
| 2025-04-28 | 1:0.0333333 |